High-dose VP-16-213 monotherapy for refractory germinal malignancies: A phase II study
作者： S N Wolff , D H Johnson , J D Hainsworth , F A Greco
关键词:
摘要: VP-16-213 at standard dose is one of the more active agents for treatment germ cell tumors. In previous phase I studies, has been investigated in suprastandard when hematopoietic reconstitution was assured by autologous bone marrow transplantation (ABMT). This II study performed to explore possibility that an augmented may be than against Eleven patients with progressive refractory tumors were treated high-dose VP-16-213: 2,400 mg/m2 ABMT every three four weeks followed 1,200 without ABMT. Seven had received prior VP-16-213. Toxicity included severe myelosuppression, nausea, vomiting, alopecia, mucositis, and hepatitis. Of 10 evaluable patients, two complete responses partial responses, all short duration, obtained. However, some unresponsive standard-dose exhibited re...
elsevier.com
sci-hub.se 参考文章(10)
Lawrence H. Einhorn, Testicular Cancer as a Model for a Curable Neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture Cancer Research. ,vol. 41, pp. 3275- 3280 ,(1981)
Stephen D Williams, Lawrence H Einhorn, F Anthony Greco, Robert Oldham, Ronald Fletcher, None, VP-16–213 salvage therapy for refractory germinal neoplasms Cancer. ,vol. 46, pp. 2154- 2158 ,(1980) , 10.1002/1097-0142(19801115)46:10<2154::AID-CNCR2820461008>3.0.CO;2-3
John D. Hainsworth, F.Anthony Greco, Testicular germ cell neoplasms The American Journal of Medicine. ,vol. 75, pp. 817- 832 ,(1983) , 10.1016/0002-9343(83)90413-8
G. Blijham, G. Spitzer, J. Litam, A.R. Zander, D.S. Verma, L. Vellekoop, M.L. Samuels, K.B. McCredie, K.A. Dicke, The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support European Journal of Cancer (1965). ,vol. 17, pp. 433- 441 ,(1981) , 10.1016/0014-2964(81)90252-8
E.S. Newlands, K.D. Bagshawe, EPIPODOPHYLLIN DERIVATIVE (VP 16-213) IN MALIGNANT TERATOMAS AND CHORIOCARCINOMAS The Lancet. ,vol. 310, pp. 87- 87 ,(1977) , 10.1016/S0140-6736(77)90088-5
Peter J. O'Dwyer, Brian Leyland-Jones, M. Teresa Alonso, Silvia Marsoni, Robert E. Wittes, Etoposide (VP-16–213) New England Journal of Medicine. ,vol. 312, pp. 692- 700 ,(1985) , 10.1056/NEJM198503143121106
LAWRENCE H. EINHORN, Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer Annals of Internal Medicine. ,vol. 87, pp. 293- 298 ,(1977) , 10.7326/0003-4819-87-3-293
Armando Santoro, Gianni Bonadonna, Valeria Bonfante, Pinuccia Valagussa, Alternating drug combinations in the treatment of advanced Hodgkin's disease. The New England Journal of Medicine. ,vol. 306, pp. 770- 775 ,(1982) , 10.1056/NEJM198204013061303
Hammond D, Krivit W, Chard Rl, Bleyer Wa, Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report. Cancer treatment reports. ,vol. 63, pp. 1755- ,(1979)
Aisner J, Van Echo Da, Wiernik Ph, High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia. Cancer clinical trials. ,vol. 3, pp. 325- ,(1980)